Trxade Group Inc. [MEDS] is -7.58% lower this YTD. Is it still time to buy?

Trxade Group Inc. [NASDAQ: MEDS] traded at a high on 11/10/20, posting a 41.86 gain after which it closed the day’ session at $6.10. The company report on November 10, 2020 that TRxADE Group to Present at the Virtual Fall Investor Summit.

Trxade Group, Inc. (MEDS) an integrated drug procurement, delivery and healthcare platform, today announced that management will present at the Virtual Fall Investor Summit, hosted by Investor Summit Group and taking place November 16-18, 2020.

Suren Ajjarapu, Chief Executive Officer of TRxADE Group, is scheduled to participate in one-on-one meetings throughout the event and will host a virtual presentation as follows:.

The results of the trading session contributed to over 30753281 shares changing hands. Over the past one week, the price volatility of Trxade Group Inc. stands at 14.65% while the volatility over the past one month is 11.18%.

The market cap for MEDS stock reached $47.15 million, with 8.06 million shares outstanding and 3.12 million shares in the current float. Compared to the average trading volume of 91.60K shares, MEDS reached a trading volume of 30753281 in the most recent trading day, which is why market watchdogs consider the stock to be active.

What do top market gurus say about Trxade Group Inc. [MEDS]?

The Average True Range (ATR) for Trxade Group Inc. is set at 0.68, with the Price to Sales ratio for MEDS stock in the period of the last 12 months amounting to 2.81. The Price to Book ratio for the last quarter was 4.55, with the Price to Cash per share for the same quarter was set at 0.85.

How has MEDS stock performed recently?

Trxade Group Inc. [MEDS] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 43.53. With this latest performance, MEDS shares gained by 0.66% in over the last four-week period, additionally plugging by 2.18% over the last 6 months – not to mention a rise of 7.01% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for MEDS stock in for the last two-week period is set at 59.15, with the RSI for the last a single of trading hit 66.10, and the three-weeks RSI is set at 56.10 for Trxade Group Inc. [MEDS]. The present Moving Average for the last 50 days of trading for this stock 5.56, while it was recorded at 4.72 for the last single week of trading, and 6.10 for the last 200 days.

Trxade Group Inc. [MEDS]: Deeper insight into the fundamentals

Operating Margin for any stock indicates how profitable investing would be, and Trxade Group Inc. [MEDS] shares currently have an operating margin of +6.64 and a Gross Margin at +65.50. Trxade Group Inc.’s Net Margin is presently recorded at -3.82.

Return on Total Capital for MEDS is now 14.46, given the latest momentum, and Return on Invested Capital for the company is -8.86. Return on Equity for this stock declined to -11.41, with Return on Assets sitting at -7.29. When it comes to the capital structure of this company, Trxade Group Inc. [MEDS] has a Total Debt to Total Equity ratio set at 24.10. Additionally, MEDS Total Debt to Total Capital is recorded at 19.42, with Total Debt to Total Assets ending up at 17.91. Long-Term Debt to Equity for the company is recorded at 21.99, with the Long-Term Debt to Total Capital now at 17.72.

Reflecting on the efficiency of the workforce at the company, Trxade Group Inc. [MEDS] managed to generate an average of -$9,808 per employee. Receivables Turnover for the company is 12.13 with a Total Asset Turnover recorded at a value of 1.91.Trxade Group Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 14.80 and a Current Ratio set at 19.90.

Earnings analysis for Trxade Group Inc. [MEDS]

With the latest financial reports released by the company, Trxade Group Inc. posted 0/share EPS, while the average EPS was predicted by analysts to be reported at 0/share. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for MEDS.

Insider trade positions for Trxade Group Inc. [MEDS]

There are presently around $4 million, or 8.70% of MEDS stock, in the hands of institutional investors. The top three institutional holders of MEDS stocks are: HEARTLAND ADVISORS INC with ownership of 300,000, which is approximately 50% of the company’s market cap and around 29.40% of the total institutional ownership; ROYCE & ASSOCIATES LP, holding 218,000 shares of the stock with an approximate value of $1.33 million in MEDS stocks shares; and G2 INVESTMENT PARTNERS MANAGEMENT LLC, currently with $0.51 million in MEDS stock with ownership of nearly New of the company’s market capitalization.

Positions in Trxade Group Inc. stocks held by institutional investors increased at the end of October and at the time of the October reporting period, where 9 institutional holders increased their position in Trxade Group Inc. [NASDAQ:MEDS] by around 241,602 shares. Additionally, 2 investors decreased positions by around 379 shares, while 2 investors held positions by with 460,913 shares. The mentioned changes placed institutional holdings at 702,894 shares, according to the latest SEC report filing. MEDS stock had 5 new institutional investments in for a total of 98,445 shares, while 2 institutional investors sold positions of 379 shares during the same period.

Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on skype
Skype
Share on reddit
Reddit

Leave a Comment

Your email address will not be published. Required fields are marked *

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam